神经分泌生物科学 NBIX 深 沪
等待开盘 10-06 09:30:00 美东时间
144.21
+1.030
+0.72%
华盛通- 最 高160.425
- 今 开142.94
- 成交量 152.94万股
- 最 低 136.31
- 昨 收 143.18
- 总市值 1378.31万
- 52周最高 186.12
- 市盈率 静 157.57
- 换手率 1600.21%
- 52周最低 122.1375
- 委 比 -46.60%
- 总股本 9.56万
- 历史最高 186.12
- 量 比 0.86
- 振 幅 16.84%
- 历史最低 1.10
- 每 手 1
- 风险率 14.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Neurocrine Buys Soleno To Tap High-Growth Rare Disease Market
Neurocrine (NBIX) to acquire Soleno Therapeutics (SLNO) for $2.9B to expand its rare disease portfolio. Get the deal details here.
04-06 20:13
Neurocrine Biosciences Agrees To Acquire Soleno Therapeutics For $53/Share, With Equity Value Of $2.9B
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) and Soleno Therapeutics, Inc. (NASDAQ:SLNO) today announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash,
04-06 19:07
'Neurocrine Nears $2.5bn-Plus Deal For Biotech Behind Obesity Disorder Treatment' - FT
https://www.ft.com/content/6642c09c-12df-4724-8ed4-a28c32b9b2b7?syn-25a6b1a6=1
04-06 16:21
Preview: Neurocrine Biosciences's Earnings
Neurocrine Biosciences (NASDAQ:NBIX) is gearing up to announce its quarterly ea...
02-11 00:01
Neurocrine BiosciencesInitiates Phase 2 Clinical Study Evaluating NBI-1065890
This Phase 2, randomized, double-blind, placebo-controlled study will enroll approximately 100 adult subjects with TD and will assess the efficacy, safety, and tolerability of NBI-1065890 compared with placebo. The
01-26 21:38
Neurocrine Biosciences Presents Head-to-Head INGREZZA Capsules Data
INGREZZA showed a nearly two-fold higher VMAT2 occupancy, consistent with greater potency when compared to AUSTEDO XR (deutetrabenazine) after a single dose of each treatmentVMAT2 occupancy is a key measurement thought
01-15 21:36
Crinetics Experimental Pill Slashes Hormones In Rare Adrenal Disease Trial
Crinetics Pharmaceuticals reported positive topline results from Phase 2 studies of atumelnant for CAH and ACTH-dependent Cushing's syndrome.
01-06 00:00
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile
Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but showed good safety and strong Q3 financial results.
2025-11-12 01:51
Earnings Scheduled For October 28, 2025
Companies Reporting Before The Bell • PayPal Holdings (NASDAQ:PYPL) is expected...
2025-10-28 19:11
Neurocrine Biosciences Provides Update on ERUDITE™Phase 2 Data For Luvadaxistat
Second Phase 2 Study for Luvadaxistat Fails to Meet Primary Endpoint as Potential Treatment for Cognitive Impairment Associated with SchizophreniaResults Confounded by Variability in Cognition Measures Across Population
2024-09-13 04:11
